Management of Postthrombolysis Hemorrhagic and Orolingual Angioedema Complications

Cumara B. O'carroll, Maria I. Aguilar

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Intravenous recombinant tissue plasminogen activator was first approved for the treatment of acute ischemic stroke in the United States in 1996. Thrombolytic therapy has been proven to be effective in acute ischemic stroke treatment and shown to improve long-term functional outcomes. Its use is associated with an increased risk of symptomatic intracerebral hemorrhage as well as orolingual angioedema. Our goal is to outline the management strategies for these postthrombolysis complications.

Original languageEnglish (US)
Pages (from-to)133-141
Number of pages9
JournalThe Neurohospitalist
Issue number3
StatePublished - Jul 2015


  • cerebrovascular disorders
  • clinical specialty
  • intracranial hemorrhages
  • neurohospitalist
  • stroke

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Management of Postthrombolysis Hemorrhagic and Orolingual Angioedema Complications'. Together they form a unique fingerprint.

Cite this